Muscular dystrophies

CONTINUUM Lifelong Learning in Neurology

Volumn 12, Issue 3, 2006, Pages 33-75

  Darras, Basil T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; CREATINE; CREATINE KINASE; CYCLOSPORIN; DEFLAZACORT; DOXYCYCLINE; DYSTROPHIN; GABAPENTIN; GENTAMICIN; MEXILETINE; OXANDROLONE; PHENYTOIN; PREDNISONE; PROCAINAMIDE; PTC 124; QUINIDINE; TOCAINAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BECKER MUSCULAR DYSTROPHY; BEHAVIOR CHANGE; BONE MARROW SUPPRESSION; CATARACT; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CRICOPHARYNGEUS MUSCLE; CUSHINGOID SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; ELECTROMYOGRAPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GASTROINTESTINAL SYMPTOM; GENE IDENTIFICATION; GENE MUTATION; GROWTH RETARDATION; HUMAN; HYPERTENSION; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE FUNCTION; MUSCULAR DYSTROPHY; MYOGLOBINURIA; MYOTOMY; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PATHOPHYSIOLOGY; QUADRICEPS FEMORIS MUSCLE; SIDE EFFECT; STEM CELL TRANSPLANTATION; WEIGHT GAIN;

EID: 33745587817     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000290463.88961.11     Document Type: Article

References (119)

1. Arahata K, Ishihara T, Kamakura K, et al. Mosaic expression of dystrophin in symptomatic carriers of Duchenne's muscular dystrophy. N Engl J Med 1989;320:138-142.
2. Arahata K, Ishiura S, Ishiguro T, et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1988;333:861-863.
3. Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005;15:86-87.
4. Backman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy (BMD). Neuromuscul Disord 1995;5:233-241. Study proving the effectiveness of lower doses of prednisolone in Becker muscular dystrophy (BMD).
5. Barton E, Zadel M, Welch E, et al. PTC124 nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD) [abstract]. Neurology 2005;54(suppl 1):A176.
6. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-381. Study identifying a treatment regimen of gentamicin, which resulted in the presence of dystrophin in cell membranes on cultured muscle cells from the mdx mouse, demonstrating that aminoglycosides can suppress stop codons in vivo.
7. Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004;63:1939-1941. Retrospective study found cardiac rhythm disturbances as early as the second decade of life in both congenital/infantile forms of myotonic dystrophy and asymptomatic patients.
8. Beenakker EA, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005;62:128-132. Prednisone 10 days per month slowed deterioration of muscle function in patients with Duchenne muscular dystrophy (DMD).
9. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002;71:1033-1043. Describes subset of patients with Walker-Warburg syndrome found to have mutations in the POMT1 gene.
10. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med 1987;316:1186-1191.
11. Biggar WD, Bachrach LK, Henderson RC, et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005;15:80-85.
12. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004;14:476-482. Deflazacort dose of 0.9 mg/kg/d was found more effective than 0.6 mg/kg administered 20 days per month.
13. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994;8:323-327. Report in five patients of unique genetic mutation resulting in the loss of all or part of the protein emerin.
14. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of def lazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-1347.
15. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-288. Locus for Emery-Dreifuss muscular dystrophy-autosomal dominant is mapped to region on chromosome 1q11-q23 containing the lamin A/C gene.
16. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculo-pharyngeal muscular dystrophy. Nat Genet 1998;18:164-167.
17. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808. Identifies a CTG triplet repeat that undergoes expansion in myotonic dystrophy patients and is located in an mRNA encoding a polypeptide that is a member of the protein kinase family.
18. Brooke M. A clinician's view of neuromuscular disease. Baltimore: Williams & Wilkins, 1986.
19. Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord 1995;5:71-74.
20. Bushby KM, Beckmann JS. The limb girdle muscular dystrophies - proposal for a new nomenclature. Neuromusc Disord 1995;5:337-343.
21. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy: I: natural history. J Neurol 1993;240:98-104. Report of clinical findings in 67 patients with BMD.
22. Bushby K, Muntoni F, Urtizberea A, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy: defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004;14:526-534.
23. Camacho Vanegas O, Bertini E, Zhang RZ, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 2001;98:7516-7521. Study describing gene mutations leading to severe reduction of collagen type VI and Ullrich congenital muscular dystrophy.
24. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne dystrophy: a systematic review. BMC Neurol 2003;3:7. Review and meta-analysis shows deflazacort improves strength and motor function more than placebo in children with Duchenne dystrophy.
25. Cartier L, Hernandez JE, Stuardo A, et al. [Quadriceps myopathy: a type of late focal dystrophy in a case]. Rev Med Chil 1995;123:81-84.
26. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-925. Demonstration of reduced incidence of side effects in once-weekly dosing.
27. Danielis R, Lazzarino LG, Nicolai A, Valassi F. Quadriceps myopathy: report of a late onset sporadic case. Riv Neurol 1991;61:51-53.
28. Darras BT. Molecular genetics of Duchenne and Becker muscular dystrophy. J Pediatr 1990;117:1-15. A review article describing the genetic features of DMD and BMD.
29. Darras BT, Jones HR. Diagnosis of neuromuscular disorders in the era of DNA analysis. Pediatr Neurol 2000;23:289-300. This review discusses the current diagnostic approach for neuromuscular disorders and describes the roles of muscle biopsy and electromyography in the presence of new genetic tests.
30. Darras BT, Menache C, Kunkel LM. Dystrophinopathies. In: Jones HR, De Vivo DC, Darras BT, eds. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach. Philadelphia: Butterworth Heinemann, 2003;649.
31. Davies JE, Wang L, Garcia-Oroz L, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005;11:672-677.
32. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne muscular dystrophy: long-term benefit. Arch Neurol 1987;44:818-822.
33. Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. J Bone Joint Surg Am 2005;87:2267-2275. Describes procedure in which scapula is fused to thorax with resulting initial elimination of scapular winging and shoulder fatigue and pain.
34. Dobyns WB, Pagon RA, Armstrong D, et al. Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet 1989;32:195-210. Review of over 60 patients with Walker-Warburg syndrome expands the phenotype and revises diagnostic criteria.
35. Dubowitz V. 47th ENMC International Workshop: treatment of muscular dystrophy. Neuromusc Disord 1997;7:261-267.
36. Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003;27:624-627.
37. Fenichel G, Pestronk A, Florence J, et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997;48:1225-1226.
38. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
39. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001;56:1075-1079.
40. Ferlini A, Sewry C, Melis MA, et al. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999;9:339-346.
41. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;15:456-465. Recommendations for the prevention of secondary complications in DMD.
42. Fukunaga H, Kitajima I, Sonoda Y, Atuchi H. [Unknown cause of familiar neuromuscular disease with infiltration of cytotoxic/suppressor T cells]. Rinsho Shinkeigaku 1990;30:654-658.
43. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002;110:339-348.
44. Gold R, Kress W, Meurers B, et al. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992;15:214-218.
45. Gospe SM Jr, Lazaro RP, Lava NS, et al. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. Neurology 1989;39:1277-1280.
46. Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy: a review of promising progress. Expert Opin Biol Ther 2003;3:803-814.
47. Griggs RC, Davis RJ, Anderson DC, Dove JT. Cardiac conduction in myotonic dystrophy. Am J Med 1975;59:37-42. Study of 26 patients with myotonic dystrophy found that first-degree heart block preceded clinical presentation of the disease in seven patients.
48. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993a;43:520-527. Report of a trial of prednisone and azathioprine designed to assess the longer-term effects of prednisone and to determine whether azathioprine, alone or in combination with prednisone, improves strength.
49. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-388.
50. Griggs RC, Tawil R, Storvick D, et al. Genetics of facioscapulohumeral muscular dystrophy: new mutations in sporadic cases. Neurology 1993b;43:2369-2372.
51. Gussoni E, Bennett RR, Muskiewicz KR, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002;110:807-814.
52. Gussoni E, Blau HM, Kunkel LM. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 1997;3:970-977.
53. Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999;401:390-394.
54. Harper PS. Myotonic dystrophy. 2nd edition. London: WB Saunders, 1989.
55. Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995;11:216-218. Study mapping the mutated gene and identifying the encoded protein in classical congenital muscular dystrophy.
56. Hewitt JE, Lyle R, Clark LN, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 1994;3:1287-1295. Description of the D4Z4 sequence, which may not encode a protein but where deletions within this locus are associated with facioscapulohumeral muscular dystrophy.
57. Hirawat S, Northcutt VJ, Welch EM, et al. Phase 1 multiple-dose safety and PK study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD) [abstract]. Neurology 2005;54:A176.
58. Hoffman EP, Kunkel LM, Angelini C, et al. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989;39:1011-1017. Examination of dystrophin in muscle biopsies from 97 patients with a diagnosis of possible BMD suggests dystrophin analysis is required for accurately distinguishing between Becker dystrophy and clinically similar autosomal recessive myopathies.
59. Hoogerwaard EM, van der Wouw PA, Wilde AA, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999;9:347-351. A study underlining cardiac involvement as part of the dystrophinopathies.
60. Hopkins LC, Jackson JA, Elsas LJ. Emery-Dreifuss humeroperoneal muscular dystrophy: an X-linked myopathy with unusual contractures and bradycardia. Ann Neurol 1981;10:230-237. Presents clinical, electromyographic, and muscle biopsy findings in the two largest known families with Emery-Dreifuss humeroperoneal muscular dystrophy.
61. Jones K, North K. The congenital muscular dystrophies. In: Jones HR, De Vivo DC, Darras BT, eds. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach. Philadelphia: Butterworth Heinemann, 2003;633.
62. Ketenjiam AY. Scapulocostal stabilization for scapular winging in facioscapulohumeral dystrophy. J Bone Joint Surg 1978;60:476-480.
63. Kissel JT, Burrow KL, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology 1991;41:667-672.
64. Kissel JT, Lynn DJ, Rammohan KW, et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 1993;43:532-536.
65. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998;394:388-392. Describes incidence, genetic locus, and mutated gene in Fukuyama congenital muscular dystrophy.
66. Kohler J, Rohrig D, Bathke KD, Koch MC. Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments. Clin Genet 1999;55:88-94. Identifies a genetic test with 100% specificity for facioscapulohumeral muscular dystrophy.
67. Korf BR, Darras BT, Urion DK. Dystrophinopathies. In: GeneReviews: medical genetics knowledge base [online]. Updated March 24, 2004 [accessed February 10, 2006]. Available: http://www.genetests.org/profiles/dbmd.
68. Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet 2002;32:235-236. Report associating facioscapulohumeral muscular dystrophy solely with the 4qA allele.
69. Louis M, Lebacq J, Poortmans JR, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003;27:604-610. Study of creatine monohydrate as potential treatment in muscular dystrophies.
70. Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000;289:1769-1773.
71. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10:35-44. Study using a transgenic mouse model of myotonic dystrophy proposes that loss of chloride channel protein from the sarcolemma may result in myotonia.
72. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004:CD003725.
73. Matsuda C, Aoki M, Hayashi YK, et al. Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology 1999;53:1119-1122. Report showing that antibodies to dysferlin identify a protein of approximately 230 kd located in the muscle membrane and not likely to be an integral component of the dystrophin complex.
74. Melacini P, Fanin M, Danieli GA, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996;94:3168-3175.
75. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597. Concludes that prednisone improves the strength and function of patients with DMD.
76. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003;53:537-542. Describes range of clinical features appearing in limb-girdle and congenital muscular dystrophies.
77. Merlini L, Cicognani A, Malaspina E, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003;27:222-227. Recommends low-dose prednisone treatment as soon as DMD diagnosis is made.
78. Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy: deflazacort trial. Neuromuscul Disord 1991;1:261-266.
79. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-368. Describes eight patients from two different families with limb-girdle muscular dystrophy 1C, associated with a severe deficiency of caveolin-3 in muscle fibers.
80. Moxley RT 3rd. Channelopathies. Curr Treat Options Neurol 2000;2:31-47.
81. Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20. Recommendations for immunosuppressive therapy in the treatment of DMD (Appendix A).
82. Muntoni F, Cau M, Ganau A, et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329:921-925.
83. Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003;13:129-132. Recommends surveillance for dilated cardiomyopathy in female carriers.
84. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004;5:872-876.
85. Palmucci L, Doriguzzi C, Mongini T, et al. Dilating cardiomyopathy as the expression of Xp21 Becker type muscular dystrophy. J Neurol Sci 1992;111:218-221.
86. Quinlivan R, Roper H, Davie M, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy: its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72-79.
87. Rafaelle Di Barletta M, Ricci E, Galluzzi G, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000;66:1407-1412. Reports that heterozygote mutations in LMNA, the gene for autosomal dominant Emery-Dreifuss muscular dystrophy, may cause diverse phenotypes ranging from typical Emery-Dreifuss muscular dystrophy to no phenotypical effect.
88. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995;17:39-43.
89. Richard I, Broux O, Allemand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27-40. Report demonstrates that an enzymatic rather than a structural protein defect causes a muscular dystrophy, a defect that may have regulatory consequences, perhaps in signal transduction.
90. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995;52:25-31.
91. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448-1452.
92. Rowland LP, Fetell M, Olarte M, et al. Emery-Dreifuss muscular dystrophy. Ann Neurol 1979;5:111-117.
93. Saito M, Kawai H, Akaike M, et al. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996;132:642-647.
94. Santavuori P, Somer H, Sainio K, et al. Muscle-eye-brain disease (MEB). Brain Dev 1989;11:147-153. Describes clinical features of muscle-eye-brain disease in 19 patients.
95. Schwartz M, Hertz JM, Sveen ML, et al. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 2005;64:1635-1637. Screening study found fukutin-related protein gene mutation in a percentage of patients negative for dystrophin gene mutations.
96. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993;43:527-532.
97. Skuk D, Roy B, Goulet M, et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004;9:475-482.
98. Sunohara N, Arahata K, Hoffman EP, et al. Quadriceps myopathy: forme fruste of Becker muscular dystrophy. Ann Neuro 1990;28:634-639. Describes four patients with a myopathy involving predominantly but not exclusively the quadriceps; all four patients had deletions of the dystrophin gene, and dystrophin deficiency was proved by immunoblot analysis.
99. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857.
100. Tarnopolsky MA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004;62:1771-1777. Report of a randomized, controlled, cross-over trial of 30 boys with DMD treated with creatine and placebo.
101. Tawil R, Figlewicz DA, Griggs RC, et al. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Ann Neurol 1998;43:279-282. Describes the observed allele in facioscapulohumeral muscular dystrophy of one to 10 residual units resulting from deletion of integral number of D4Z4 repeat units, implying the presence of a potentially novel molecular pathogenesis.
102. Taylor DA, Carroll JE, Smith ME, et al. Facioscapulohumeral dystrophy associated with hearing loss and Coats syndrome. Ann Neurol 1982;12:395-398.
103. Thornton CA, Griggs RC, Moxley RT 3rd. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994;35:269-272.
104. Tidball JG, Spencer MJ. Skipping to new gene therapies for muscular dystrophy. Nat Med 2003;9:997-998.
105. Tome FM, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 1994;317:351-357. Describes a specific absence of merosin, the laminin M chain, in 13 patients affected by a classical non-Japanese form of congenital muscular dystrophy.
106. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998;10:131-139.
107. Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854-1865. Initial description of a large family who had dilated cardiomyopathy with no evidence of skeletal myopathy, and resulting linkage analysis.
108. van der Maarel SM, Frants RR. The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy. Am J Hum Genet 2005;76:375-386. Postulates that D4Z4 contraction leads to inappropriate expression of one or more disease genes.
109. van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 2003;4:774-783.
110. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003;35:315-317.
111. Vervoort VS, Holden KR, Ukadike KC, et al. POMGnTI gene alterations in a family with neurological abnormalities. Ann Neurol 2004;56:143-148. Identification of novel POMGnT1 gene alterations in a family affected with congenital hypotonia, early-onset glaucoma, and psychomotor delays.
112. Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy: familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 1962;267:1267-1272.
113. von Mitzlaff HC, Liechti-Gallati S, Rosler KM, Burgunder JM. [Quadriceps myopathy as dystrophin-associated myopathy]. Schweiz Med Wochenschr 1993;123:1865-1869.
114. Wada Y, Itoh Y, Furukawa T, et al. "Quadriceps myopathy": a clinical variant form of Becker muscular dystrophy. J Neurol 1990;237:310-312.
115. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-711.
116. Walter MC, Lochmuller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology 2000;54:1848-1850.
117. Wicksell RK, Kihlgren M, Melin L, Eeg-Olofsson O. Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev Med Child Neurol 2004;46:154-159.
118. Wu ZY, Wang ZQ, Wang N, et al. [Study on EcoR I fragment polymorphism of the subtelomeric domains within 4q35 and 10q26 with pulsed field gel electrophoresis in the Chinese population.] Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004;21:552-556.
119. Yoshida K, Ikeda S, Nakamura A, et al. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve 1993;16:1161-1166.